Loading clinical trials...
Loading clinical trials...
A PHASE 1/2, RANDOMIZED, OBSERVER-BLINDED STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF COMBINED VACCINE CANDIDATES AGAINST INFLUENZA AND COVID-19 IN HEALTHY INDIVIDUALS
Conditions
Interventions
Investigational Influenza Vaccine
COVID-19 Vaccine
+4 more
Locations
22
United States
Orange County Research Center
Lake Forest, California, United States
Artemis Institute for Clinical Research
San Diego, California, United States
Diablo Clinical Research, Inc.
Walnut Creek, California, United States
Clinical Research Consulting
Milford, Connecticut, United States
Indago Research & Health Center, Inc
Hialeah, Florida, United States
Miami Dade Medical Research Institute, LLC
Miami, Florida, United States
Start Date
November 11, 2024
Primary Completion Date
July 15, 2025
Completion Date
July 15, 2025
Last Updated
August 15, 2025
NCT06631287
NCT05101213
NCT04565665
NCT06871293
NCT04978571
NCT07221162
Lead Sponsor
BioNTech SE
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions